Tumour marker tests measure proteins in the blood that can indicate cancer risk or tumour activity. At Bids Chemist, these tests support early detection and ongoing monitoring for various cancers. Quick, accurate results give you peace of mind and help guide timely medical action and treatment if required.
This test measures alpha-fetoprotein (AFP), a protein produced by the liver and yolk sac during fetal development. In adults, elevated AFP may indicate liver disease, liver cancer, or certain germ cell Tumours. Blood is drawn, and results are interpreted alongside imaging and other clinical evaluations. Monitoring AFP assists healthcare providers in early disease detection, assessing treatment response, and guiding follow-up care. Patients benefit by understanding risk factors and ensuring timely management of liver or testicular conditions. The test is also used to monitor high-risk patients, enabling preventative strategies and early interventions.
This test measures beta-2 microglobulin in serum, a protein associated with kidney function and immune system activity. Elevated levels may indicate renal disease, immune disorders, or certain cancers. Blood is collected and analysed to guide diagnosis, monitor progression, and inform treatment planning. Understanding beta-2 microglobulin levels helps healthcare providers assess organ function, detect underlying disease, and implement preventive or therapeutic strategies. Patients benefit from early detection and tailored health management.
This test measures cancer antigen 125 (CA-125), a protein often elevated in ovarian cancer and other gynecologic conditions. Blood is drawn, and results help healthcare providers monitor disease presence, progression, or response to treatment. CA-125 is used alongside imaging and clinical evaluation. Early detection supports timely interventions, guides therapy decisions, and improves patient outcomes. Patients benefit from understanding risk factors, monitoring health, and engaging in proactive cancer screening.
This test measures cancer antigen 15-3 (CA 15-3), a protein marker commonly used to monitor breast cancer. Blood is drawn, and elevated levels may indicate Tumour activity or recurrence. Results help healthcare providers assess treatment response, detect disease progression, and plan ongoing management. Patients benefit from early identification, monitoring therapy effectiveness, and implementing proactive care strategies to improve long-term outcomes.
This test measures cancer antigen 19-9 (CA 19-9), a protein used to monitor pancreatic or gastrointestinal cancers. Blood is drawn, and elevated levels may suggest Tumour activity or disease progression. Results help healthcare providers track treatment response, guide further investigations, and monitor for recurrence. Patients benefit from early detection, improved monitoring, and timely interventions to optimise outcomes and support long-term cancer management.
This test measures cancer antigen 72-4 (CA 72-4), a protein marker associated with gastrointestinal and ovarian cancers. Blood is drawn and analysed to support early detection, monitor therapy response, and track disease progression. Understanding CA 72-4 levels allows healthcare providers to implement timely interventions, guide treatment, and improve long-term patient outcomes. Patients benefit from proactive monitoring and informed management of their cancer risk or treatment response.
This test measures carcinoembryonic antigen (CEA), a protein that may be elevated in colorectal, pancreatic, breast, or lung cancers. Blood is drawn, and results help healthcare providers monitor disease progression, assess treatment response, or detect recurrence. While not used as a standalone diagnostic tool, CEA testing is valuable for ongoing cancer management and risk assessment. Patients benefit from timely monitoring, early intervention, and guidance on follow-up care, improving outcomes and supporting personalised treatment planning.
This panel measures multiple female Tumour markers, proteins that may be elevated in ovarian, breast, or gynecologic cancers. Blood is drawn and analysed to help monitor disease, assess treatment response, or detect recurrence. Results guide healthcare providers in planning follow-up, early interventions, and personalised care. Patients benefit from early detection, ongoing monitoring, and improved outcomes through proactive health management.
This test measures free prostate-specific antigen (PSA), a protein produced by the prostate gland. Blood is collected to assess prostate health, monitor for benign prostatic hyperplasia, or detect early prostate cancer. Abnormal results help healthcare providers determine the need for further testing, imaging, or treatment. Patients benefit from early detection of prostate abnormalities, informed healthcare decisions, and the ability to implement preventive strategies. Monitoring free PSA supports long-term urological health and early intervention for optimal outcomes.
This test measures multiple male Tumour markers in the blood, which may indicate risk or presence of cancers affecting the prostate, testes, or other reproductive organs. Blood is drawn and analysed to monitor for disease progression, recurrence, or early detection of malignancy. Results guide healthcare providers in recommending further diagnostic testing, treatment planning, and preventive measures. Patients benefit by gaining awareness of potential malignancies, allowing timely interventions, reducing long-term complications, and maintaining overall health. Regular monitoring supports informed decisions, improves early detection rates, and empowers patients to engage in proactive management of male reproductive and overall wellness.
This test measures neuron-specific enolase (NSE), a protein found in neurons and neuroendocrine cells. Blood is collected to detect neuronal damage, brain injury, or certain neuroendocrine Tumours. Elevated NSE may indicate conditions such as stroke, traumatic brain injury, or cancer. Early detection helps healthcare providers diagnose, monitor progression, and guide treatment. Patients benefit by identifying potential nervous system issues early, enabling timely intervention, preserving cognitive and neurological function, and supporting long-term health. Monitoring NSE is particularly valuable in patients with neurological symptoms, enabling proactive care planning, targeted therapy, and prevention of complications. Timely assessment contributes to overall wellness and early detection of disease.
This prostate profile evaluates multiple markers related to male reproductive health, including PSA and other Tumour or hormone indicators. Blood is collected and analysed to assess prostate function, screen for malignancy, and detect early disease. Results help healthcare providers guide treatment decisions, preventive measures, or lifestyle recommendations. Patients benefit by understanding prostate health, identifying potential issues early, and implementing interventions to maintain long-term urinary and reproductive wellness. Early detection supports timely management, reduces risk of complications, and ensures optimal long-term male hea
This test measures total prostate-specific antigen (PSA) in the blood, a key marker for prostate health. Elevated levels may indicate benign prostatic hyperplasia, inflammation, or potential malignancy. Blood is collected and analysed to guide further diagnostic testing, treatment planning, and monitoring. Patients benefit by identifying potential prostate issues early, receiving timely interventions, and maintaining long-term urinary and reproductive health. Regular monitoring supports informed decision-making and proactive management of prostate wellness.
